Akili Interactive
Carebook reports record revenue and the first quarter of positive adjusted EBITDA, while Cue Health sees large net and adjusted EBITDA losses.
The company also announced its intentions to seek FDA approval for EndeavorOTC, its over-the-counter product for adults with ADHD.
Boehringer Ingelheim and Click Therapeutics initiate clinical trial on PDTx treatment for schizophrenia and Akili's EndeavorRx shows promise for adults with ADHD.
During Venture Connect at HIMSS23, panelists discussed the future of digital therapeutics.
Earlier this year, the prescription digital therapeutics company said it would put programs related to cognitive health outside of ADHD on hold.
The prescription digital therapeutics company will also put non-ADHD products in development on hold to "conserve capital and focus."
Matt Franklin, Akili Interactive's president and COO, explains the company's strategy for launching EndeavorRx, its video game digital therapeutic for children with ADHD.
The newly public company, now trading on Nasdaq under the ticker symbol "AKLI," will use the proceeds from the transaction to launch EndeavorRx, its video game-like digital therapeutic for children with ADHD.
Also: CVS Health hires Tilak Mandadi for the newly created role of chief data, digital and technology officer.
The study did not find find a significant difference in depression symptoms between the intervention and control group.